Drug-induced liver injury: past, present and future
Pharmacogenomics – 10 years of progress: a cardiovascular perspective
Rheumatoid arthritis pharmacogenomics
Pharmacogenomics of paclitaxel
The past, present and future of pharmacoepigenomics
MicroRNAs and pharmacogenomics
Applying the genome to national drug formulary policy in the developing world
Biobanking and pharmacogenomics
Cost–effectiveness analysis in pharmacogenomics
Pharmacogenetics education: 10 years of experience at Tel Aviv University
Direct-to-consumer genome testing: opportunities for pharmacogenomics research?
Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice
Breaking new ground in inflammatory bowel disease genetics: genome-wide association studies and beyond
MicroRNAs in diagnosis and prognosis in cancer: what does the future hold?
Alzheimer's disease susceptibility genes may be triggered by isoflurane anesthesia
CEP17 mutation indicates anthracycline susceptibility in breast cancer tumors
Drug-metabolizing enzymes: if they work together, they should be tested together
Radiotherapy risks recurrence in ATM -mutated breast cancer patients
Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2–2 genotype
HTR2C promoter polymorphisms are associated with risperidone efficacy in Chinese female patients
Role of genetic variation in the cannabinoid type 1 receptor gene ( CNR1 ) in the pathophysiology of human obesity
CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation
Acknowledgements
Corrigendum